Back to Search
JOSEPH SHAUGHNESSY, MD
MD
Family Medicine Physician
NPI: 1336236900IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
ME61407(FL)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIFORMED SERVICES UHS FE HEBERT SCHOOL OF MED
Class of 1990
Research & Publications (20)
Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin.
PMID 19273554·Infect Immun·2009
8-other
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.
PMID 19657367·Leukemia·2009
8-other
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
PMID 19636021·J Clin Oncol·2009
8-other
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
PMID 19344415·Br J Haematol·2009
8-other
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
PMID 19443657·Blood·2009
3-trial
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
PMID 19389881·Blood·2009
8-other
The molecular characterization and clinical management of multiple myeloma in the post-genome era.
PMID 19657360·Leukemia·2009
6-review
The role of Dickkopf-1 in bone development, homeostasis, and disease.
PMID 18687985·Blood·2009
6-review
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
PMID 19458357·Blood·2009
7-preclinical
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
PMID 19228610·Blood·2009
8-other
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
PMID 19196662·Blood·2009
7-preclinical
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.
PMID 19191868·Eur J Haematol·2009
8-other
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
PMID 19171872·Blood·2009
8-other
Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols.
PMID 19120351·Br J Haematol·2009
8-other
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
PMID 19016584·J Bone Miner Res·2009
7-preclinical
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
PMID 19388929·Br J Haematol·2009
7-preclinical
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.
PMID 19597185·Blood·2009
7-preclinical
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
PMID 19515721·Blood·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 930 KINGSLEY AVE
ORANGE PARK, FL 32073 - Phone
- (904) 269-0500
Quick Facts
- NPI
- 1336236900
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile